<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.98142</article-id><article-id pub-id-type="publisher-id">ACM-31600</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190800000_26713599.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  GABAA受体效应与新生儿癫癎治疗
  The Effect of GABAA Receptor and Its Treatment of Neonatal Epilepsy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>肖</surname><given-names>潇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>曼丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>汤</surname><given-names>继宏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>苏州大学附属儿童医院，江苏 苏州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>08</month><year>2019</year></pub-date><volume>09</volume><issue>08</issue><fpage>926</fpage><lpage>930</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    近年来的研究显示苯巴比妥类等针对性作用于GABA
   <sub>A</sub>受体的药物在新生儿癫癎治疗中的临床疗效不佳，且可能导致进一步的远期脑损害，原因在于新生脑中GABA
   <sub>A</sub>受体表现为兴奋性效应，随着神经系统发育而逐渐转化为成熟脑中的重要抑制性受体。位于神经元细胞膜上的转运蛋白NKCC1、KCC2及L型Ca
   <sup>2+</sup>通道共同参与了新生期GABA
   <sub>A</sub>受体激活后兴奋性效应的形成。
    The drug phenobarbital which acts as GABA
   <sub>A</sub> receptor modulator is recently found to have a poor clinical outcome and even a long-term injury to brain. The reason may lie on the excitatory effect of GABA
   <sub>A</sub> receptor in developing brain rather than the inhibitory effect in developed brain. Trans-porter NKCC1 and KCC2 along with L-type Ca
   <sup>2+</sup> channel take part in the generation of the excitatory effect, which indicates a new way of target therapy of neonatal epilepsy. 
  
 
</p></abstract><kwd-group><kwd>新生儿癫癎，GABAA受体，治疗，NKCC1, Neonatal Epilepsy</kwd><kwd> GABAA Receptor</kwd><kwd> Treatment</kwd><kwd> NKCC1</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>GABA<sub>A</sub>受体效应与新生儿癫癎治疗<sup> </sup></title><p>肖潇，王曼丽，汤继宏<sup>*</sup></p><p>苏州大学附属儿童医院，江苏 苏州</p><p><img src="//html.hanspub.org/file/6-1570991x1_hanspub.png" /></p><p>收稿日期：2019年7月15日；录用日期：2019年7月31日；发布日期：2019年8月7日</p><disp-formula id="hanspub.31600-formula22"><graphic xlink:href="//html.hanspub.org/file/6-1570991x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>近年来的研究显示苯巴比妥类等针对性作用于GABA<sub>A</sub>受体的药物在新生儿癫癎治疗中的临床疗效不佳，且可能导致进一步的远期脑损害，原因在于新生脑中GABA<sub>A</sub>受体表现为兴奋性效应，随着神经系统发育而逐渐转化为成熟脑中的重要抑制性受体。位于神经元细胞膜上的转运蛋白NKCC1、KCC2及L型Ca<sup>2+</sup>通道共同参与了新生期GABA<sub>A</sub>受体激活后兴奋性效应的形成。</p><p>关键词 :新生儿癫癎，GABA<sub>A</sub>受体，治疗，NKCC1</p><disp-formula id="hanspub.31600-formula23"><graphic xlink:href="//html.hanspub.org/file/6-1570991x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/6-1570991x8_hanspub.png" /> <img src="//html.hanspub.org/file/6-1570991x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 背景</title><p>癫癎(epilepsy)是一种临床常见的以神经元细胞异常放电导致惊厥(seizures)反复发作为特征的神经系统疾病，是由于脑内兴奋性/抑制性递质失衡、神经网络异常激活所致 [<xref ref-type="bibr" rid="hanspub.31600-ref1">1</xref>] 。文献报道癫癎的发病机制与神经系统的成熟度有关，新生儿期癫癎发病率高于其他各年龄组 [<xref ref-type="bibr" rid="hanspub.31600-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.31600-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.31600-ref4">4</xref>] 。然而，新生儿期癫癎反复发作将进一步导致皮层神经网络结构和功能的损害，增加抽搐易感性、影响远期认知发育，并导致远期行为及学习功能异常 [<xref ref-type="bibr" rid="hanspub.31600-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.31600-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.31600-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.31600-ref8">8</xref>] 。此外，新生儿期癫癎同时亦是儿童期难治性癫癎的重要危险因素 [<xref ref-type="bibr" rid="hanspub.31600-ref9">9</xref>] ，故其治疗在临床工作中长期受到重视。</p></sec><sec id="s4"><title>2. GABA<sub>A</sub>能药物在新生儿癫癎治疗中的疗效及远期作用存疑</title><p>γ-氨基丁酸(gamma-aminobutyric acid, GABA)是中枢神经系统内主要的抑制性递质之一，通过结合其离子通道型受体GABA<sub>A</sub>及代谢型受体GABA<sub>B</sub>在全脑各个区域广泛影响着各种神经生理及病理过程 [<xref ref-type="bibr" rid="hanspub.31600-ref10">10</xref>] 。多年以来，提高GABA能的抑制作用是癫癎临床治疗的重要思路，而以GABA受体为标靶的临床药物则广泛应用于癫癎的治疗。这其中最重要的莫过于以经典抗癫癎药物苯巴比妥类及苯二氮卓类、神经类固醇类等作用于GABA<sub>A</sub>受体复合物的药物 [<xref ref-type="bibr" rid="hanspub.31600-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.31600-ref11">11</xref>] 。特别是苯巴比妥及苯妥英，长期被WHO推荐为成人、儿童及新生儿抗癫癎的一线用药 [<xref ref-type="bibr" rid="hanspub.31600-ref12">12</xref>] 。</p><p>但近年的报道显示，由于新生儿神经系统发育不完善的特殊性，苯巴比妥类等作用于GABA<sub>A</sub>受体复合物的的经典抗癫癎药物在新生儿癫癎治疗中的疗效远不及年长儿及成人 [<xref ref-type="bibr" rid="hanspub.31600-ref13">13</xref>] ，甚至可能导致进一步的远期脑损害 [<xref ref-type="bibr" rid="hanspub.31600-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.31600-ref15">15</xref>] 。如Ikonomidou等的研究团队验证了苯巴比妥对新生大鼠中枢神经系统的影响，结果提示新生期应用苯巴比妥可能会影响神经系统发育，继而诱导神经元细胞凋亡 [<xref ref-type="bibr" rid="hanspub.31600-ref16">16</xref>] 。</p></sec><sec id="s5"><title>3. GABA<sub>A</sub>能药物对新生儿癫癎疗效不佳的可能与其兴奋性效应有关</title><p>GABA<sub>A</sub>能药物在新生儿癫癎治疗中的不良表现可能与GABA<sub>A</sub>受体在未成熟中枢神经系统中表现为兴奋性效应有关。近年来已有多项体内及体外研究显示，未成熟脑中GABA<sub>A</sub>受体活性表现为兴奋性，并随着脑发育的成熟，其对神经元细胞的作用逐渐从兴奋性转向抑制性 [<xref ref-type="bibr" rid="hanspub.31600-ref17">17</xref>] 。而经典的抗癫癎药物如苯巴比妥类、苯二氮卓类及神经类固醇类等通过增强GABA<sub>A</sub>受体效应，在成熟脑中稳定神经元细胞膜电位达到抑制惊厥发作的作用，但在新生脑中效应则可能相反。故苯巴比妥类等GABA能药物对新生儿癫癎疗效不佳。此现象在数项体内及体外实验中均得到证实 [<xref ref-type="bibr" rid="hanspub.31600-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.31600-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.31600-ref19">19</xref>] 。</p><p>GABA能效应的转化由Na<sup>+</sup>, K<sup>+</sup>/2Cl<sup>−</sup>协同转运蛋白(Na<sup>+</sup>-K<sup>+</sup>-2Cl<sup>−</sup> cotransporter 1, NKCC1)和K<sup>+</sup>/Cl<sup>−</sup>协同转运蛋白(KCC2)的在新生脑内的差异性表达决定 [<xref ref-type="bibr" rid="hanspub.31600-ref17">17</xref>] 。在未成熟神经元细胞中，介导Cl<sup>-</sup>向神经元细胞内摄取的NKCC1高表达，同时介导Cl<sup>−</sup>向细胞外转运的KCC2低表达，使细胞内Cl<sup>−</sup>浓度增高。当GABA<sub>A</sub>受体开放，Cl<sup>−</sup>外流，细胞膜去极化，则神经元细胞兴奋性增高。而在神经元细胞逐渐成熟后，NKCC1和KCC2的表达此消彼长，细胞内Cl<sup>-</sup>浓度较细胞外高，GABA<sub>A</sub>受体开放则导致Cl<sup>−</sup>内流，细胞膜超极化，神经元细胞兴奋性降低。同时，未成熟神经元细胞中的GABA<sub>A</sub>受体的激活引起瞬时Ca<sup>2+</sup>流入神经元细胞内，继而进一步促进了细胞膜去极化 [<xref ref-type="bibr" rid="hanspub.31600-ref20">20</xref>] ，使神经元细胞兴奋性增高。</p><p>研究显示，GABA<sub>A</sub>受体介导的膜去极化兴奋性作用是未成熟脑相比成熟脑更易出现惊厥发作的重要原因之一 [<xref ref-type="bibr" rid="hanspub.31600-ref21">21</xref>] ，此效应同时与神经发育过程中突触可塑性及兴奋性的调节密切相关 [<xref ref-type="bibr" rid="hanspub.31600-ref22">22</xref>] 。在哺乳动物的发育过程中，脑内GABA能系统对神经元细胞兴奋性到抑制性作用的转换对大脑功能的最终完善非常重要。与此同时，未成熟脑内其他未成熟的电压和递质门控通道(如N-甲基-D-天冬氨酸受体，即NMDA受体等)、突触结构、神经网络和各类支持性神经胶质细胞等，和GABA的兴奋性效应共同导致未成熟脑的兴奋性增高，增加了抽搐的发生几率 [<xref ref-type="bibr" rid="hanspub.31600-ref6">6</xref>] 。</p></sec><sec id="s6"><title>4. GABA在新生脑内的兴奋性效应提示了新的药物研究方向</title><p>NKCC1及KCC2在新生脑内的差异性表达共同导致了GABA的去极化兴奋性效应，提示作用于此二类转运蛋白的药物也许将成为特异性针对新生儿癫癎的新药物靶点 [<xref ref-type="bibr" rid="hanspub.31600-ref23">23</xref>] 。</p><p>Yamada等曾报道新生新皮层神经元细胞内Cl<sup>−</sup>的浓度与NKCC1 mRNA的表达正相关，而与KCC2的表达负相关。应用NKCC1特异性抑制剂布美他尼可抑制NKCC1对Cl−向细胞内转运，降低神经元细胞内Cl<sup>−</sup>的浓度 [<xref ref-type="bibr" rid="hanspub.31600-ref24">24</xref>] 。Succol和Tyzio等研究者也相继验证过类似结论 [<xref ref-type="bibr" rid="hanspub.31600-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.31600-ref26">26</xref>] 。NKCC1对GABA受体效应的调节作用亦在NKCC1敲除的小鼠谱系 [<xref ref-type="bibr" rid="hanspub.31600-ref27">27</xref>] 和在体NKCC1 RNA干扰抑制实验 [<xref ref-type="bibr" rid="hanspub.31600-ref28">28</xref>] 中得到验证。Kahle等曾报道过一例单用布美他尼治疗新生儿抽搐的病例，结果显示单用布美他尼可缩短抽搐持续时间，降低抽搐频率，同时亦未引起明确副作用 [<xref ref-type="bibr" rid="hanspub.31600-ref29">29</xref>] 。此外亦有研究报道NKCC1特异性抑制剂布美他尼能提高新生期抽搐治疗中GABA<sub>A</sub>受体正调质(如经典抗癫癎药物苯巴比妥)的疗效 [<xref ref-type="bibr" rid="hanspub.31600-ref30">30</xref>] 。有关布美他尼对新生脑的远期细胞形态、功能及神经行为学的影响仍需进一步研究 [<xref ref-type="bibr" rid="hanspub.31600-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.31600-ref32">32</xref>] [<xref ref-type="bibr" rid="hanspub.31600-ref33">33</xref>] 。</p><p>相比NKCC1，对KCC2的研究则不够充分。有研究显示对新生大鼠应用KCC2拮抗剂或抑制KCC2在神经元细胞膜上的表达可维持GABA<sub>A</sub>受体介导的去极化效应、推迟GABA<sub>A</sub>效应从兴奋性向抑制性的转化 [<xref ref-type="bibr" rid="hanspub.31600-ref34">34</xref>] [<xref ref-type="bibr" rid="hanspub.31600-ref35">35</xref>] ，但由于至今未找到特异性KCC2激动剂，KCC2激动剂能否逆转新生脑内GABA<sub>A</sub>兴奋性效应则至今尚无确切研究结论 [<xref ref-type="bibr" rid="hanspub.31600-ref36">36</xref>] 。</p><p>此外，未成熟皮质神经元细胞中的GABA<sub>A</sub>受体的激活引起的Ca<sup>2+</sup>瞬时内流应可被L型Ca<sup>2+</sup>通道阻滞剂尼莫地平(nimodipine)和硝苯地平(nifedipine)阻滞 [<xref ref-type="bibr" rid="hanspub.31600-ref37">37</xref>] 。这提示L型Ca<sup>2+</sup>通道阻滞剂或许能通过抑制神经元细胞膜去极化，甚至促进细胞膜超极化，从而降低细胞膜兴奋性，针对性治疗新生儿癫癎。</p></sec><sec id="s7"><title>5. 总结</title><p>综上所述，GABA<sub>A</sub>受体在未成熟脑内表现为兴奋性效应，而非传统观念认为的抑制性效应。作为GABA<sub>A</sub>受体正调质的经典抗癫癎药物如苯巴比妥类及苯二氮卓类在新生儿中疗效不佳，甚至可能进一步诱导兴奋性脑损伤及远期行为学改变，故针对新生儿癫癎的治疗方案亟需更新。特异性作用于脑内NKCC1及KCC2蛋白及L型Ca<sup>2+</sup>通道阻滞剂的药物可望成为新一代抗新生儿癫癎的重要药物。</p></sec><sec id="s8"><title>文章引用</title><p>肖 潇,王曼丽,汤继宏. GABAA受体效应与新生儿癫癎治疗The Effect of GABAA Receptor and Its Treatment of Neonatal Epilepsy[J]. 临床医学进展, 2019, 09(08): 926-930. https://doi.org/10.12677/ACM.2019.98142</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.31600-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Staley, K. (2015) Molecular Mechanisms of Epilepsy. Nature Neuroscience, 18, 367. &lt;br&gt;https://doi.org/10.1038/nn.3947</mixed-citation></ref><ref id="hanspub.31600-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Dang, L.T. and Silverstein, F.S. (2017) Drug Treatment of Seizures and Ep-ilepsy in Newborns and Children. Pediatric Clinics of North America, 64, 1291-1308. &lt;br&gt;https://doi.org/10.1016/j.pcl.2017.08.007</mixed-citation></ref><ref id="hanspub.31600-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bell, G.S., Neligan, A. and Sander, J.W. (2014) An Unknown Quantity—The Worldwide Prevalence of Epilepsy. Epilepsia, 55, 958-962. &lt;br&gt;https://doi.org/10.1111/epi.12605</mixed-citation></ref><ref id="hanspub.31600-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Vento, M., de Vries, L.S., Alberola, A., et al. (2009) Approach to Seizures in the Neonatal Period: A European Perspective. Acta Paediatrica, 99, 497-501. &lt;br&gt;https://doi.org/10.1111/j.1651-2227.2009.01659.x</mixed-citation></ref><ref id="hanspub.31600-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Vezzani, A., Aronica, E., Mazarati, A. and Pittman, Q.J. (2013) Epilepsy and Brain Inflammation. Experimental Neurology, 244, 11-21. &lt;br&gt;https://doi.org/10.1016/j.expneurol.2011.09.033</mixed-citation></ref><ref id="hanspub.31600-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Nardou, R., Ferrari, D.C. and Ben-Ari, Y. (2013) Mecha-nisms and Effects of Seizures in the Immature Brain. Seminars in Fetal &amp; Neonatal Medicine, 18, 175-184. &lt;br&gt;https://doi.org/10.1016/j.siny.2013.02.003</mixed-citation></ref><ref id="hanspub.31600-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Miller, S.M., Goasdoue, K. and Björkman, S.T. (2017) Neonatal Seizures and Disruption to Neurotransmitter Systems. Neural Regeneration Research, 12, 216-217. &lt;br&gt;https://doi.org/10.4103/1673-5374.200803</mixed-citation></ref><ref id="hanspub.31600-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Dupuis, N. and Auvin, S. (2015) Inflammation and Epilepsy in the Developing Brain: Clinical and Experimental Evidence. CNS Neuroscience &amp; Therapeutics, 21, 141-151. &lt;br&gt;https://doi.org/10.1111/cns.12371</mixed-citation></ref><ref id="hanspub.31600-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Whitehead, E., Dodds, L., Joseph, K.S., et al. (2006) Relation of Pregnancy and Neonatal Factors to Subsequent Development of Childhood Epilepsy: A Population-Based Cohort Study. Pediatrics, 117, 1298-1306.  
&lt;br&gt;https://doi.org/10.1542/peds.2005-1660</mixed-citation></ref><ref id="hanspub.31600-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Jembrek, M.J. and Vlainic, J. (2015) GABA Receptors: Pharmaco-logical Potential and Pitfalls. Current Pharmaceutical Design, 21, 4943-4959. &lt;br&gt;https://doi.org/10.2174/1381612821666150914121624</mixed-citation></ref><ref id="hanspub.31600-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Chuang, S.H. and Reddy, D.S. (2018) Genetic and Molecular Regulation of Extrasynaptic GABA-A Receptors in the Brain: Therapeutic Insights for Epilepsy. Journal of Pharmacology and Experimental Therapeutics, 364, 180-197.  
&lt;br&gt;https://doi.org/10.1124/jpet.117.244673</mixed-citation></ref><ref id="hanspub.31600-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2013) Standard Antiepileptic Drugs (Phenobarbital, Pheny-Toin, Carbamazepine, Valproic Acid) for Management of Convulsive Epilepsy in Adults and Children in WHO Mental Health Gap Action Programme mhGAP, mhGAP Evidence Resource Center, Epilepsy and Seizures. WHO, Geneva.</mixed-citation></ref><ref id="hanspub.31600-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Glykys, J. and Staley, K.J. (2015) Diazepam Effect during Early Neonatal Development Correlates with Neuronal Cl-. Annals of Clinical and Translational Neurology, 2, 1055-1070. &lt;br&gt;https://doi.org/10.1002/acn3.259</mixed-citation></ref><ref id="hanspub.31600-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Vesoulis, Z.A. and Mathur, A.M. (2014) Advances in Management of Ne-onatal Seizures. Indian Journal of Pediatrics, 81, 592-598. &lt;br&gt;https://doi.org/10.1007/s12098-014-1457-9</mixed-citation></ref><ref id="hanspub.31600-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Sands, T.T. and Mcdonough, T.L. (2016) Recent Advances in Neonatal Seizures. Current Neurology and Neuroscience Reports, 16, 92. &lt;br&gt;https://doi.org/10.1007/s11910-016-0694-x</mixed-citation></ref><ref id="hanspub.31600-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ikonomidou, C. (2009) Triggers of Apoptosis in the Immature Brain. Brain &amp; Development, 31, 488-492.  
&lt;br&gt;https://doi.org/10.1016/j.braindev.2009.02.006</mixed-citation></ref><ref id="hanspub.31600-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Kirmse, K., Witte, O.W. and Holthoff, K. (2011) GABAergic Depolarization during Early Cortical Development and Implications for Anticonvulsive Therapy in Neonates. Epilepsia, 52, 1532-1543.  
&lt;br&gt;https://doi.org/10.1111/j.1528-1167.2011.03128.x</mixed-citation></ref><ref id="hanspub.31600-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Wang, D.D. and Kriegstein, A.R. (2011) Blocking Early GABA Depolarization with Bumetanide Results in Permanent Alterations in Cortical Circuits and Sensorimotor Gating Deficits. Cerebral Cortex, 21, 574-587.  
&lt;br&gt;https://doi.org/10.1093/cercor/bhq124</mixed-citation></ref><ref id="hanspub.31600-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Chamma, I., Chevy, Q., Poncer, J.C., et al. (2012) Role of the Neuronal K-Cl Co-Transporter KCC2 in Inhibitory and Excitatory Neurotransmission. Frontiers in Cellular Neuroscience, 6, 5. &lt;br&gt;https://doi.org/10.3389/fncel.2012.00005</mixed-citation></ref><ref id="hanspub.31600-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Kirmse, K., Witte, O.W. and Holthoff, K. (2010) GABA Depolarizes Immature Neocortical Neurons in the Presence of the Ketone Body β-Hydroxybutyrate. Journal of Neuroscience, 30, 16002-16007.  
&lt;br&gt;https://doi.org/10.1523/JNEUROSCI.2534-10.2010</mixed-citation></ref><ref id="hanspub.31600-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Holmes, G.L. (2009) The Long-Term Effects of Neonatal Seizures. Clinics in Perinatology, 36, 901-904.  
&lt;br&gt;https://doi.org/10.1016/j.clp.2009.07.012</mixed-citation></ref><ref id="hanspub.31600-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Kalkman, H.O. (2011) Alterations in the Expression of Neuronal Chloride Transporters May Contribute to Schizophrenia. Progress in Neuro-Psychopharmacology &amp; Biological Psy-chiatry, 35, 410-414.  
&lt;br&gt;https://doi.org/10.1016/j.pnpbp.2011.01.004</mixed-citation></ref><ref id="hanspub.31600-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Hernan, A.E. and Holmes, G.L. (2016) Antiepileptic Drug Treatment Strategies in Neonatal Epilepsy. Progress in Brain Research, 226, 179-193. &lt;br&gt;https://doi.org/10.1016/bs.pbr.2016.03.011</mixed-citation></ref><ref id="hanspub.31600-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Yamada, J., Okabe, A., Toyoda, H., Kilb, W., Luhmann, H.J. and Fukuda, A. (2004) Cl− Uptake Promoting Depolarizing GABA Actions in Immature Rat Neocortical Neurones Is Me-diated by NKCC1. The Journal of Physiology, 557, 829-841. &lt;br&gt;https://doi.org/10.1113/jphysiol.2004.062471</mixed-citation></ref><ref id="hanspub.31600-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Succol, F., Fiumelli, H., Benfenati, F., et al. (2012) Intracellular Chloride Concentration Influences the GABAA Receptor Subunit Composition. Nature Communications, 3, 738. &lt;br&gt;https://doi.org/10.1038/ncomms1744</mixed-citation></ref><ref id="hanspub.31600-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Tyzio, R., Nardou, R., Ferrari, D.C., et al. (2014) Oxytocin-Mediated GABA Inhibition during Delivery Attenuates Autism Pathogenesis in Rodent Offspring. Science, 343, 675-679. &lt;br&gt;https://doi.org/10.1126/science.1247190</mixed-citation></ref><ref id="hanspub.31600-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Sipila, S.T., Huttu, K., Yamada, J., et al. (2009) Compensatory En-hancement of Intrinsic Spiking upon NKCC1 Disruption in Neonatal Hippocampus. Journal of Neuroscience, 29, 6982-6988.  
&lt;br&gt;https://doi.org/10.1523/JNEUROSCI.0443-09.2009</mixed-citation></ref><ref id="hanspub.31600-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Wang, D.D. and Kriegstein, A.R. (2008) GABA Regu-lates Excitatory Synapse Formation in the Neocortex via NMDA Receptor Activation. Journal of Neuroscience, 28, 5547-5558. &lt;br&gt;https://doi.org/10.1523/JNEUROSCI.5599-07.2008</mixed-citation></ref><ref id="hanspub.31600-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Kahle, K.T., Barnett, S.M., Sassower, K.C., et al. (2009) Decreased Seizure Activity in a Human Neonate Treated with Bumetanide, an Inhibitor of the NAt-Kt-2Cle Cotransporter NKCC1. Journal of Child Neurology, 24, 572e6.  
&lt;br&gt;https://doi.org/10.1177/0883073809333526</mixed-citation></ref><ref id="hanspub.31600-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Cleary, R.T., Sun, H., Huynh, T., et al. (2013) Bumetanide En-hances Phenobarbital Efficacy in a Rat Model of Hypoxic Neonatal Seizures., PLoS ONE, 8, e57148. &lt;br&gt;https://doi.org/10.1371/journal.pone.0057148</mixed-citation></ref><ref id="hanspub.31600-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Löscher, W., Puskarjov, M. and Kaila, K. (2013) Cation-Chloride Cotransporters NKCC1 and KCC2 as Potential Targets for Novel Antiepileptic and Antiepileptogenic Treatments. Neuropharmacology, 69, 62-74.  
&lt;br&gt;https://doi.org/10.1016/j.neuropharm.2012.05.045</mixed-citation></ref><ref id="hanspub.31600-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Pressler, R.M., Boylan, G.B., Marlow, N., et al. (2015) Bumetanide for the Treatment of Seizures in Newborn Babies with Hypoxic Ischaemic Encephalopathy (NEMO, an Open-Label, Dose Finding, and Feasibility Phase 1/2 Trial. The Lancet Neurology, 14, 469-477. &lt;br&gt;https://doi.org/10.1016/S1474-4422(14)70303-5</mixed-citation></ref><ref id="hanspub.31600-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Thoresen, M. and Sabir, H. (2015) Epilepsy: Neonatal Seizures Still Lack Safe and Effective Treatment. Nature Reviews Neurology, 11, 311-312. &lt;br&gt;https://doi.org/10.1038/nrneurol.2015.74</mixed-citation></ref><ref id="hanspub.31600-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Friedel, P., Kahle, K.T., Zhang, J.W., et al. (2015) WNK1-Regulated Inhibitory Phosphorylation of the KCC2 Cotransporter Maintains the Depolarizing Action of GABA in Immature Neurons. Science Signaling, 8, ra65.  
&lt;br&gt;https://doi.org/10.1126/scisignal.aaa0354</mixed-citation></ref><ref id="hanspub.31600-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Furukawa, M., Tsukahara, T., Tomita, K., et al. (2017) Neonatal Maternal Separation Delays the GABA Excitatory-to-Inhibitory Functional Switch by Inhibiting KCC2 Expression. Biochemical and Biophysical Research Communications, 493, 1243-1249. &lt;br&gt;https://doi.org/10.1016/j.bbrc.2017.09.143</mixed-citation></ref><ref id="hanspub.31600-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Puskarjov, M., Kahle, K.T., Ruusuvuori, E., et al. (2014) Pharmacotherapeutic Targeting of Cation-Chloride Cotransporters in Neonatal Seizures. Epilepsia, 55, 806-818. &lt;br&gt;https://doi.org/10.1111/epi.12620</mixed-citation></ref><ref id="hanspub.31600-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Kim, D.Y., Fenoglio, K.A., Simeone, T.A., et al. (2008) GABAA Receptor-Mediated Activation of L-Type Calcium Channels Induces Neuronal Excitation in Surgically Resected Human Hypothalamic Hamartomas. Epilepsia, 49, 861-871. &lt;br&gt;https://doi.org/10.1111/j.1528-1167.2007.01455.x</mixed-citation></ref></ref-list></back></article>